
The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
For Tsuruha, being a shareholder really comes down to believing in the long-term appeal of its drugstore model and its ability to integrate past deals while keeping returns to equity holders attractive. The latest first quarter numbers, with sales jumping to ¥636,886 million but earnings per share slipping, sit awkwardly against earlier guidance that implied smoother profit progression. In the near term, the key catalysts remain how efficiently Tsuruha converts that larger revenue base into margins, and how the Aeon and Welcia relationships translate into store productivity rather than just scale. The share price has already rebounded in recent weeks, which suggests the market does not see this quarter as a thesis breaker, but the dilution over the past year and still-modest return on equity keep execution risk firmly in focus.
However, the recent dilution and lower EPS trend carry implications investors should not ignore. Tsuruha Holdings' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.The Simply Wall St Community has just one very large fair value estimate for Tsuruha at ¥12,935, pointing to a far higher outcome than current levels. That sits against the near term concern that EPS has fallen despite strong sales growth, which raises questions about how effectively this expanding business model will translate into shareholder returns over time.
Explore another fair value estimate on Tsuruha Holdings - why the stock might be worth over 5x more than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com